Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer.

Gökmen-Polar Y, Goswami CP, Toroni RA, Sanders KL, Mehta R, Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW Jr.

J Cancer. 2014 Aug 15;5(8):633-45. doi: 10.7150/jca.8466. eCollection 2014.

2.

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, Lucero OM, Chien AJ, Moon RT.

J Clin Invest. 2014 Jul;124(7):2877-90. doi: 10.1172/JCI70156. Epub 2014 May 27.

3.

Protein kinase PKN1 represses Wnt/β-catenin signaling in human melanoma cells.

James RG, Bosch KA, Kulikauskas RM, Yang PT, Robin NC, Toroni RA, Biechele TL, Berndt JD, von Haller PD, Eng JK, Wolf-Yadlin A, Chien AJ, Moon RT.

J Biol Chem. 2013 Nov 29;288(48):34658-70. doi: 10.1074/jbc.M113.500314. Epub 2013 Oct 10.

4.

WLS inhibits melanoma cell proliferation through the β-catenin signalling pathway and induces spontaneous metastasis.

Yang PT, Anastas JN, Toroni RA, Shinohara MM, Goodson JM, Bosserhoff AK, Chien AJ, Moon RT.

EMBO Mol Med. 2012 Dec;4(12):1294-307. doi: 10.1002/emmm.201201486. Epub 2012 Nov 6.

5.

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.

Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW Jr.

Breast Cancer Res Treat. 2012 Dec;136(3):673-82. doi: 10.1007/s10549-012-2298-8. Epub 2012 Oct 21.

PMID:
23085766
6.

Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.

Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, Robin NC, Dawson DW, Moon RT, Chien AJ.

Sci Signal. 2012 Jan 10;5(206):ra3. doi: 10.1126/scisignal.2002274.

7.

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.

Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD.

Breast Cancer Res Treat. 2011 Jun;127(2):375-84. doi: 10.1007/s10549-010-1004-y. Epub 2010 Jul 3.

PMID:
20602165

Supplemental Content

Loading ...
Support Center